Targeting histone deacetylases: development of vorinostat for the treatment of cancer (Q37961738)

26 August 2017

title

Targeting histone deacetylases: development of vorinostat for the treatment of cancer (English)

1 reference

26 August 2017

Victoria M Richon

1

1 reference

26 August 2017

publication date

1 June 2010

1 reference

26 August 2017

1 reference

26 August 2017

volume

2

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

457-465

1 reference

Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.

26 August 2017

cites work

1 reference

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

21 January 2018

1 reference

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

Development of vorinostat: current applications and future perspectives for cancer therapy

21 January 2018

1 reference

The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men

21 January 2018

1 reference

Lysine acetylation targets protein complexes and co-regulates major cellular functions

21 January 2018

1 reference

Expression profile of histone deacetylase 1 in gastric cancer tissues.

21 January 2018

1 reference

Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer

21 January 2018

1 reference

HDAC3 overexpression and colon cancer cell proliferation and differentiation

21 January 2018

1 reference

Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues

21 January 2018

1 reference

The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression.

21 January 2018

1 reference

Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia

21 January 2018

1 reference

A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition

21 January 2018

1 reference

An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1.

21 January 2018

1 reference

Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA

21 January 2018

1 reference

Role for histone deacetylase 1 in human tumor cell proliferation

21 January 2018

1 reference

Epigenetic modifiers: basic understanding and clinical development.

21 January 2018

1 reference

Chemical phylogenetics of histone deacetylases

21 January 2018

1 reference

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

Romidepsin for the treatment of cutaneous T-cell lymphoma

21 January 2018

1 reference

Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines

21 January 2018

1 reference

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

21 January 2018

1 reference

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

21 January 2018

1 reference

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.

21 January 2018

1 reference

Acetylation inactivates the transcriptional repressor BCL6.

21 January 2018

1 reference

Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation

21 January 2018

1 reference

Enhancing the apoptotic and therapeutic effects of HDAC inhibitors

21 January 2018

1 reference

Apoptotic and autophagic cell death induced by histone deacetylase inhibitors

21 January 2018

1 reference

Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling

21 January 2018

1 reference

Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma

21 January 2018

1 reference

Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells.

21 January 2018

1 reference

Vorinostat enhances the antimyeloma effects of melphalan and bortezomib

21 January 2018

1 reference

Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma

21 January 2018

1 reference

Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat

21 January 2018

1 reference

Rational combinations using HDAC inhibitors

21 January 2018

1 reference

DNA methylation and gene silencing in cancer

21 January 2018

1 reference

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

21 January 2018

1 reference

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells

21 January 2018

1 reference

Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.

21 January 2018

1 reference

Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed

21 January 2018

1 reference

A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer

21 January 2018

1 reference

A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy

21 January 2018

1 reference

Novel therapies in the treatment of multiple myeloma

21 January 2018

1 reference

The development of proteasome inhibitors as anticancer drugs

21 January 2018

1 reference

Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.

21 January 2018

1 reference

The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress

21 January 2018

1 reference

Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species

21 January 2018

1 reference

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors

21 January 2018

1 reference

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

21 January 2018

1 reference

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

21 January 2018

1 reference

Vorinostat in solid and hematologic malignancies

21 January 2018

1 reference

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

21 January 2018

1 reference

New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer

21 January 2018

1 reference

A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer

21 January 2018

1 reference

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

21 January 2018

1 reference

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

21 January 2018

1 reference

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study

21 January 2018

1 reference

Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma

21 January 2018

1 reference

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma

21 January 2018

1 reference

Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials

21 January 2018

1 reference

Mutations truncating the EP300 acetylase in human cancers

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/EPI.10.20

1 reference

26 August 2017

1 reference